Adam Boehler, director of the Center for Medicare & Medicaid Innovation, is taking on an additional role as the senior advisor for value-based transformation and innovation. He represents the last departmental appointment as part of HHS Secretary Alex Azar's 4 priority areas.
Adam Boehler, who is currently director of the Center for Medicare & Medicaid Innovation (CMMI), will take on a new role that will help transform the US healthcare system to a value-based one. HHS Secretary Alex Azar announced that Boehler will also serve as the senior advisor for value-based transformation and innovation.
In March, Azar had announced 4 initiatives that were key departmental priorities: combatting the opioid crisis, bringing down the cost of prescription drugs, addressing the cost and availability of health insurance, and value-based transformation of the healthcare system.
“Adam is the kind of results-oriented, transformational leader we need to deliver on what President Trump has promised the American people: better healthcare at a lower cost,” Azar said in a statement. “At CMMI, he has already demonstrated an ambition for bold change, and will now be able to bring his deep experience with private sector innovation to help HHS execute on the long-talked-about goal of transforming our healthcare system into one that pays for value.”
Boehler represents the last senior advisor to be named to the 4 priority areas. Previously, Jim Parker was named senior advisor to the secretary for health reform and director of the Office of Health Reform, Dan Best was named senior advisor for drug pricing reform, and Brett Giroir, MD, was named senior advisor for opioid and mental health policy.
Boehler will continue to lead CMMI, which pilots, tests, and evaluates alternative payment models. He was previously the CEO and founder of Landmark Health, which was created to transform healthcare by improving quality of life in communities.
On Twitter, Boehler wrote that he was excited to expand HHS’ “efforts to move healthcare from volume to value for the benefit of the American patient.”
Charles “Chip” Kahn III, president and CEO of the Federation of American Hospitals, wrote in a blog post that Boehler has been an actual innovator and brings a fresh take on healthcare.
“I believe he is well suited for his new role as Senior Advisor for Value-Based Transformation and Innovation,” Kahn wrote.
America’s Physician Groups, which represents accountable physician groups that aim to drive the transformation of healthcare delivery, applauded the appointment.
As the transition to value is a top priority for Secretary Azar and an integral component in bending the healthcare cost curve, it is critical that HHS has an experienced and forward-leaning individual leading this effort,” Donald H. Crane, president and CEO of America’s Physician Groups, said in a statement. “Mr. Boehler is such an individual.”
FDA Commissioner Scott Gottlieb, MD, noted his support of Boehler’s new appointment.
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Specialty Drug Costs Drive Medicare Part D Dermatology Expenditures
July 22nd 2025The rapidly increasing prescriptions for expensive specialty medications, rather than their price growth, are the primary driver of escalating dermatology Medicare Part D expenditures, necessitating policies that balance innovation, access, and affordability.
Read More